Global Urokinase Market Analysis 2016-2020 and Forecast 2021-2026

Snapshot

Urokinase, also known as urokinase-type plasminogen activator (uPA), is a serine protease present in humans and other animals. The human urokinase protein was discovered, but not named, by McFarlane and Pilling in 1947. Urokinase was originally isolated from human urine, and it is also present in the blood and in the extracellular matrix of many tissues. The primary physiological substrate of this enzyme is plasminogen, which is an inactive form (zymogen) of the serine protease plasmin.
The global Urokinase market size is estimated at xxx million USD with a CAGR xx% from 2016-2020 and is expected to reach xxx Million USD in 2021 with a CAGR xx% from 2021 to 2026. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Urokinase by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.

Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):

Urokinase Powder
Urokinase Solution

Company Coverage (Company Profile, Sales Revenue, Price, Gross Margin, Main Products etc.):
Wanhua Biochem
NDPharm
Jiangxi Haoran Bio-Pharma
Jiangsu Aidea Pharmaceutical

Application Coverage (Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.):

Hospital
Clinic
Others

Region Coverage (Regional Production, Demand & Forecast by Countries etc.):

North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain etc.)
Asia-Pacific (China, India, Japan, Southeast Asia etc.)
South America (Brazil, Argentina etc.)
Middle East & Africa (Saudi Arabia, South Africa etc.)

Frequently Asked Questions